MA-891 Cells
General information
| Description | MA-891 is a highly metastatic murine mammary gland carcinoma cell line, established from a spontaneous mammary tumor in a mouse and selected for its aggressive metastatic behavior. The line grows as an adherent monolayer and is classified as a syngeneic tumor cell line compatible with immunocompetent mouse hosts, enabling in vivo studies of mammary carcinoma growth, metastasis, and immune interaction. MA-891 represents a highly metastatic variant selected for its propensity to disseminate to distant organs, particularly the lungs. MA-891 is applicable in murine mammary carcinoma research including studies of metastatic cascade biology, invasion, angiogenesis, tumor-immune interactions, and preclinical evaluation of anti-metastatic and anti-tumor agents. Its syngeneic origin enables testing of immunotherapy approaches in immunocompetent hosts, including checkpoint inhibitor evaluation and cancer vaccine development. The high metastatic potential makes it a useful model for studying metastasis prevention strategies and the biology of aggressive mammary carcinoma. |
|---|---|
| Organism | Mouse |
| Tissue | Mammary gland |
| Disease | Carcinoma |
| Metastatic site | Metastatic (high metastatic potential; primarily to lungs) |
| Applications | Murine mammary carcinoma research; metastasis biology; anti-metastatic drug evaluation; syngeneic tumor immunotherapy; tumor-immune interaction; cancer vaccine studies |
| Synonyms | Mouse Mammary Carcinoma Highly Metastatic Cell Line |
Characteristics
| Age | Age unspecified |
|---|---|
| Gender | Female |
| Ethnicity | Unspecified |
| Morphology | Epithelial-like |
| Cell type | Tumor Cell Line |
| Growth properties | Adherent |
Regulatory Data
| Citation | MA-891 (Cytion catalog number 305581) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 10090 |
Biomolecular Data
Handling
| Culture Medium | RPMI-1640 with 10% FBS; 1% Penicillin-Streptomycin Solution |
|---|---|
| Supplements | Supplement the medium with 10% FBS and 1% Penicillin-Streptomycin |
| Dissociation Reagent | Accutase |
| Doubling time | approx. 18 to 24 hours |
| Subculturing | Remove medium, wash with PBS without calcium and magnesium, cover with Accutase, incubate 8–10 min at RT, resuspend in medium, centrifuge 300×g 3 min, discard supernatant, reseed in fresh medium. |
| Split ratio | 1 to 5 |
| Seeding density | 1 to 3 × 10⁴ cells/cm² |
| Fluid renewal | Every 2 to 3 days |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
Material Transfer Agreement
If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.
For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.
Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement.